Results 251 to 260 of about 1,072,475 (388)
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad+9 more
wiley +1 more source
Effect of heart rate on B-type natriuretic peptide in sinus rhythm. [PDF]
Fukushima K+3 more
europepmc +1 more source
Corin in Natriuretic Peptide Processing and Hypertension
Yiqing Zhou, Qingyu Wu
semanticscholar +1 more source
Inhibiting atrial natriuretic peptide clearance reduces myocardial fibrosis and improves cardiac function in diabetic rats. [PDF]
Bakhos JJ+11 more
europepmc +1 more source
Atrial natriuretic peptide concentrations in pre-eclampsia:: Authors' reply [PDF]
J. K. Thomsen+4 more
openalex +1 more source
Atrial natiuretic peptid in normal humans: Hemodynamic and renal effects after single and repeated bolus injection [PDF]
Ball, P.+8 more
core
R. Rodseth+26 more
semanticscholar +1 more source
AIM This analysis provides a comparison of the efficacy of initial mono and combination therapy in patients with PAH and cardiovascular comorbidities or with risk factors of HFpEF (heart failure with preserved ejection fractioin).METHOD Data from the European COMPERA registry were used for a matched pair analysis.
Dirk Skowasch+20 more
wiley +1 more source
Abstract Aims Electron microscopy reveals microstructural alterations in cardiomyocyte nuclei and myofilaments in non‐ischaemic cardiomyopathy (NICM), particularly in dilated cardiomyopathy (DCM). Nevertheless, the correlation between such observations and clinical outcomes, including prognosis and left ventricular reverse remodelling (LVRR), remains ...
Rie Higuchi+19 more
wiley +1 more source